List of Excipients in Branded Drug SOVALDI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	SOVALDI	sofosbuvir	61958-1501	CELLULOSE, MICROCRYSTALLINE	2026-08-28
Gilead Sciences Inc	SOVALDI	sofosbuvir	61958-1501	CROSCARMELLOSE SODIUM	2026-08-28
Gilead Sciences Inc	SOVALDI	sofosbuvir	61958-1501	FERRIC OXIDE YELLOW	2026-08-28
Gilead Sciences Inc	SOVALDI	sofosbuvir	61958-1501	MAGNESIUM STEARATE	2026-08-28

Last updated: August 12, 2026

Sofosbuvir’s excipient strategy is commercially important because the product combines a high-dose, poorly water-soluble antiviral prodrug with a large global generic market. Sovaldi uses a conventional immediate-release tablet platform built around lactose, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide and sodium stearyl fumarate. The strongest opportunities are generic formulation development, excipient substitution, direct-compression optimization, fixed-dose combinations and regional manufacturing. The main barriers are bioequivalence, impurity control, solid-state consistency, patent exposure and the need to match tablet performance at a 400 mg active load.

Sovaldi Excipient Strategy and Commercial Opportunities for Sofosbuvir

What is Sovaldi and how does its formulation work?

Sovaldi is Gilead Sciences’ oral formulation of sofosbuvir, a nucleotide analog inhibitor of the hepatitis C virus NS5B polymerase. The U.S. Food and Drug Administration approved Sovaldi in December 2013 for use with other antiviral agents in adults with chronic hepatitis C virus infection.[1]

The marketed 400 mg product is a film-coated, capsule-shaped tablet. Its formulation is a conventional immediate-release solid oral dosage form rather than a modified-release, lipid-based or multiparticulate system.

Product attribute	Sovaldi 400 mg
Active ingredient	Sofosbuvir
Dosage form	Film-coated tablet
Strength	400 mg
Route	Oral
Therapeutic area	Chronic hepatitis C
Initial U.S. approval	December 2013
Manufacturer	Gilead Sciences
Release profile	Immediate release
Biological product status	Not a biologic; biosimilar pathway does not apply

Sofosbuvir is a high-dose active pharmaceutical ingredient relative to many oral antivirals. The excipient system must therefore provide tabletability, acceptable disintegration, stable drug distribution and adequate dissolution without excessive tablet mass.

What excipients are used in Sovaldi tablets?

The Sovaldi tablet core contains six listed inactive ingredients, while the film coating contains four.[2]

Excipient	Function in the Sovaldi formulation	Commercial relevance
Lactose monohydrate	Diluent and compactability aid	Supports tablet mass and compression performance
Microcrystalline cellulose	Diluent, dry binder and compression aid	Helps produce robust tablets at high drug loading
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and dissolution
Povidone	Binder	Improves granule or powder cohesion
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and may reduce processing variability
Sodium stearyl fumarate	Lubricant	Reduces tooling friction with lower hydrophobicity than some stearate lubricants
Polyvinyl alcohol	Film-forming polymer	Provides the coating matrix
Titanium dioxide	Opacifier and pigment	Controls appearance and light protection
Polyethylene glycol	Plasticizer	Improves coating flexibility
Talc	Anti-tacking and coating aid	Reduces sticking during film coating

The formulation does not depend on a novel excipient or a highly specialized delivery technology. That profile lowers development complexity for generic manufacturers, while increasing the importance of process control and comparative dissolution.

Why is Sovaldi’s excipient system commercially attractive to generic manufacturers?

The formulation uses widely available pharmaceutical excipients with established regulatory histories. Generic developers can source the principal materials from multiple global suppliers, reducing supply concentration and manufacturing cost.

The commercial attraction has four parts:

1. The active ingredient is present at a substantial 400 mg strength, creating demand for efficient direct compression or high-throughput granulation.
2. The excipients are familiar to tablet manufacturers in the United States, Europe, India, China and other regulated markets.
3. The product is immediate release, avoiding the equipment and validation burden associated with controlled-release systems.
4. Sofosbuvir is used in high-volume treatment regimens and fixed-dose combinations, creating demand beyond the standalone Sovaldi tablet.

Sovaldi generated approximately $10.3 billion in worldwide revenue for Gilead in 2014, its first full year after launch.[3] That revenue scale established a large commercial base for API, excipient and generic manufacturing suppliers, even though later competition and price reductions materially changed market economics.

What formulation challenges do Sovaldi generic developers face?

The main technical challenge is achieving bioequivalence with a tablet containing a high proportion of active ingredient and a relatively simple excipient system.

Drug loading and tablet robustness

Sofosbuvir occupies a significant share of the tablet mass. Developers must balance active loading against sufficient levels of microcrystalline cellulose, lactose, binder and disintegrant. Excessive dilution increases tablet size and manufacturing cost. Insufficient excipient content can produce friability, capping or variable disintegration.

Dissolution and solid-state control

Sofosbuvir’s aqueous solubility and dissolution behavior can be sensitive to particle size, polymorphic form, milling conditions and excipient interactions. A generic product must control:

• API particle-size distribution
• polymorphic or crystalline form
• blend uniformity
• lubricant exposure
• compression force
• disintegration time
• dissolution across relevant pH conditions

Sodium stearyl fumarate is commercially relevant because lubricant selection can influence wetting and dissolution. Over-lubrication can reduce tablet strength or slow liquid penetration.

Moisture and storage stability

Lactose, povidone and cellulose-based excipients can affect moisture uptake and tablet stability. The formulation must control water activity, packaging permeability and manufacturing humidity. A generic developer may obtain a performance advantage from a more robust blister system or a moisture-protective bottle, even without changing the core excipients.

Film-coating performance

The polyvinyl alcohol, polyethylene glycol and talc coating system is conventional. The commercial opportunity is not a novel coating chemistry but process efficiency, color matching, coating uniformity and reduced defect rates. Coating weight, spray rate, inlet temperature and tablet-bed conditions can affect appearance and mechanical protection.

What excipient substitutions could create a competitive advantage?

A generic manufacturer may substitute excipients where the regulatory filing supports the change and comparative performance remains acceptable. The most commercially relevant substitution strategies are:

Sovaldi excipient role	Potential alternative strategy	Potential benefit
Lactose diluent	Mannitol, anhydrous lactose or selected calcium phosphate grades	Lower moisture sensitivity or improved flow
Microcrystalline cellulose	Co-processed cellulose systems	Better compactability or reduced tablet size
Croscarmellose sodium	Crospovidone or sodium starch glycolate	Different disintegration and dissolution profile
Povidone binder	Copovidone or dry-binder systems	Improved powder flow or granulation efficiency
Colloidal silicon dioxide	Engineered silica grades	Better flow and reduced segregation
Sodium stearyl fumarate	Magnesium stearate or alternative low-level lubricants	Lower cost or improved supply flexibility
Polyvinyl alcohol coating	Hypromellose-based coating	Broader coating supplier availability

Substitution is not automatically an advantage. A changed excipient system can alter dissolution, stability, tablet hardness, impurity formation, scale-up behavior and regulatory comparability. The most defensible strategy is usually targeted substitution of a supply-constrained or performance-limiting excipient rather than wholesale redesign.

What patents protect Sovaldi and its formulation?

Sovaldi’s core intellectual-property position has historically centered on sofosbuvir, its nucleotide prodrug chemistry, related compounds and methods of treatment. Public patent records and FDA Orange Book data should be reviewed separately because active-ingredient patents, method-of-use patents and formulation claims have different legal and commercial effects.[4][5]

The listed product is not generally understood to depend on a complex excipient patent estate. The inactive ingredients identified in the FDA label are established pharmaceutical materials, and the label does not identify a proprietary delivery platform. This limits the value of excipient-centered patent blocking compared with the value of:

• sofosbuvir composition patents;
• prodrug and metabolite-related patents;
• crystalline-form or solid-state claims;
• manufacturing-process patents;
• hepatitis C treatment method claims;
• fixed-dose combination patents involving sofosbuvir and another antiviral.

How strong is the excipient patent estate?

The excipient-related barrier is comparatively weak because conventional lactose-cellulose-disintegrant-binder systems are difficult to monopolize broadly. Commercial protection is more likely to arise from process know-how, validated manufacturing parameters, impurity controls and regulatory data than from ownership of the individual excipients.

A generic competitor can often design around a narrow formulation claim by changing the diluent, disintegrant, lubricant, coating polymer or process sequence. A composition patent covering the active pharmaceutical ingredient presents a more substantial barrier.

When does Sovaldi lose exclusivity and how does Paragraph IV risk apply?

Sovaldi is a small-molecule drug, so generic manufacturers can submit an Abbreviated New Drug Application rather than a biosimilar application. Paragraph IV certifications may challenge Orange Book-listed patents before their expiration.[6]

The practical exclusivity analysis has several layers:

Exclusivity category	Relevance to Sovaldi
New chemical entity exclusivity	Applied after the 2013 approval and expired before the current generic market phase
Pediatric exclusivity	May extend listed patent protection where FDA granted the relevant extension
Composition-of-matter patents	Historically the most important barrier to standalone generic entry
Method-of-use patents	Can restrict labeled indications or specific treatment regimens
Formulation patents	Potentially relevant but less central than active-ingredient rights
Regulatory exclusivity for biologics	Not applicable
Generic exclusivity	May apply to the first qualifying Paragraph IV filer, depending on the approval record

The exact launch date for a generic depends on patent settlements, court decisions, certification strategy, regulatory approval and market-specific licensing. A formulation design-around does not eliminate risk from an unexpired active-ingredient or method patent.

Which companies are commercial competitors to Sovaldi?

Sovaldi competes with other direct-acting antiviral products rather than with conventional excipient-based therapies.

Product	Active ingredients	Commercial positioning
Sovaldi	Sofosbuvir	Standalone sofosbuvir platform used with other antivirals
Harvoni	Ledipasvir/sofosbuvir	Fixed-dose combination developed by Gilead
Epclusa	Velpatasvir/sofosbuvir	Broad-genotype combination
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	Retreatment and resistant-infection positioning
Mavyret	Glecaprevir/pibrentasvir	Competing pan-genotypic regimen from AbbVie
Zepatier	Elbasvir/grazoprevir	Earlier competing direct-acting antiviral

The most significant commercial substitution comes from fixed-dose combinations. A standalone sofosbuvir tablet can remain relevant where local treatment protocols, reimbursement rules or procurement systems favor modular regimens. In high-income markets, combinations reduce the role of Sovaldi as a standalone product.

What are the largest excipient and manufacturing opportunities?

Generic Sovaldi tablets

The largest opportunity is low-cost manufacture of bioequivalent 400 mg tablets for markets where generic entry is permitted. Cost savings can come from:

• high-yield direct compression;
• reduced coating weight;
• optimized excipient grades;
• lower tablet rejection rates;
• regional excipient sourcing;
• moisture-protective packaging;
• integrated API-tablet manufacturing.

Fixed-dose combination products

Sofosbuvir remains commercially valuable as a component of combination products. Excipient strategy becomes more complex when the tablet contains velpatasvir, ledipasvir or another antiviral. Developers must manage drug-drug compatibility, differing dose levels, dissolution requirements and potentially different solid forms.

Excipient supply and technical services

Suppliers can monetize the product category through:

• high-functionality microcrystalline cellulose;
• co-processed direct-compression excipients;
• low-moisture lactose grades;
• fast-disintegrating crospovidone or croscarmellose;
• low-level lubricants;
• ready-to-use film-coating systems;
• stability and dissolution consulting;
• scale-up and process-validation services.

Emerging and price-sensitive markets

Countries with high hepatitis C burdens and public procurement programs create demand for robust, low-cost formulations. Regional manufacturers may gain an advantage from local regulatory knowledge, shorter supply chains and access to voluntary licensing arrangements. Excipient suppliers that can provide consistent quality in smaller production lots may capture business from large multinational vendors.

What regulatory issues affect Sovaldi excipient strategy?

FDA generic development requires pharmaceutical equivalence and bioequivalence under the applicable ANDA pathway. Excipient changes can trigger additional comparative work when they affect dissolution, stability, impurity profiles or product performance.[6]

Key regulatory controls include:

• compliance with compendial specifications where applicable;
• excipient supplier qualification;
• elemental impurity and residual-solvent assessment;
• nitrosamine and mutagenic impurity controls;
• extractables and leachables review for packaging;
• stability under ICH conditions;
• comparative dissolution;
• content uniformity at commercial scale;
• control of API polymorphism and particle size.

FDA labeling identifies the inactive ingredients but does not make every excipient combination a protected commercial formulation. The regulatory value of an excipient strategy comes from reproducible product performance and a defensible quality-by-design package.

What generic launch scenarios exist for Sovaldi?

Three launch scenarios are commercially relevant.

Authorized or licensed generic launch

A license-backed product can enter with lower litigation risk and may use the originator’s market access, procurement relationships or manufacturing infrastructure. Margins are usually lower than those available to an unchallenged branded product.

Paragraph IV launch

A successful Paragraph IV challenge can produce an earlier launch and potential 180-day exclusivity for the first eligible generic applicant. The risk is significant litigation exposure, potential injunctions, damages and delayed commercialization.

Post-expiry or market-by-market launch

Manufacturers may launch after relevant patent expiry or under country-specific patent rules. This approach lowers litigation risk but may surrender early market share and pricing power.

Key Takeaways

• Sovaldi uses a conventional immediate-release tablet with lactose, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide and sodium stearyl fumarate.
• The formulation is commercially accessible because it relies on established, multi-source excipients.
• The central technical challenge is not excipient novelty. It is achieving consistent dissolution, stability and bioequivalence at a 400 mg active load.
• Formulation substitution can reduce cost and supply risk, but changes must be supported by comparative performance and regulatory data.
• Sofosbuvir’s strongest intellectual-property barriers have historically involved the active molecule, prodrug chemistry, treatment methods and combination products rather than individual excipients.
• Sovaldi has no biosimilar pathway because it is a small-molecule drug.
• The largest commercial opportunities are generic standalone tablets, fixed-dose combinations, regional manufacturing and high-functionality excipient supply.
• Competitive pressure from Harvoni, Epclusa, Vosevi, Mavyret and other direct-acting antivirals limits the standalone branded opportunity.

FAQs

Can a generic Sovaldi manufacturer use different excipients?

Yes. A generic developer can use alternative excipients where the formulation remains pharmaceutically equivalent, bioequivalent, stable and compliant with FDA or other applicable regulatory requirements.

Is Sovaldi protected by a proprietary coating technology?

The marketed product uses a conventional film-coating system based on polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc. The principal commercial barriers have been associated more closely with sofosbuvir intellectual property than with coating technology.

Does sofosbuvir require a special solubilizing excipient?

Sovaldi’s FDA-listed formulation does not rely on a lipid vehicle or specialized solubilization platform. Particle-size control, solid-state management, disintegration and dissolution are more important development variables.

Are excipient suppliers exposed to Sovaldi patent litigation?

Excipient suppliers generally face less direct patent exposure than API manufacturers or generic drug sponsors. Risk can arise where a supplier actively contributes to an infringing formulation or process, but conventional excipient supply is usually not the central litigation issue.

Is a sofosbuvir fixed-dose combination a larger opportunity than standalone Sovaldi?

In many markets, yes. Fixed-dose combinations such as ledipasvir/sofosbuvir and velpatasvir/sofosbuvir align with simplified treatment protocols and can protect commercial value through combination, formulation and method-of-use rights.

References

1. U.S. Food and Drug Administration. (2013). FDA approves Sovaldi for chronic hepatitis C. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). Sovaldi (sofosbuvir) prescribing information. Gilead Sciences. https://www.accessdata.fda.gov
3. Gilead Sciences, Inc. (2014). 2014 annual report. https://www.gilead.com
4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
6. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations and ANDA development guidance. https://www.fda.gov